Meeder Advisory Services Inc. Buys 66 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Meeder Advisory Services Inc. raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.3% in the first quarter, Holdings Channel.com reports. The firm owned 1,589 shares of the company’s stock after acquiring an additional 66 shares during the period. Meeder Advisory Services Inc.’s holdings in IDEXX Laboratories were worth $858,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of the stock. Valley National Advisers Inc. lifted its holdings in shares of IDEXX Laboratories by 84.6% during the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock worth $26,000 after acquiring an additional 22 shares during the period. Riverview Trust Co acquired a new stake in shares of IDEXX Laboratories during the 1st quarter worth about $26,000. DSM Capital Partners LLC acquired a new stake in shares of IDEXX Laboratories during the 4th quarter worth about $33,000. Private Wealth Management Group LLC acquired a new stake in shares of IDEXX Laboratories during the 4th quarter worth about $34,000. Finally, Venturi Wealth Management LLC increased its position in shares of IDEXX Laboratories by 226.3% during the 4th quarter. Venturi Wealth Management LLC now owns 62 shares of the company’s stock worth $34,000 after purchasing an additional 43 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Trading Up 1.0 %

IDEXX Laboratories stock traded up $5.06 during midday trading on Tuesday, hitting $487.76. 185,255 shares of the stock were exchanged, compared to its average volume of 464,037. The company has a fifty day simple moving average of $500.53 and a two-hundred day simple moving average of $521.32. IDEXX Laboratories, Inc. has a 52 week low of $372.50 and a 52 week high of $583.39. The stock has a market capitalization of $40.28 billion, a PE ratio of 47.04, a P/E/G ratio of 4.02 and a beta of 1.32. The company has a quick ratio of 1.16, a current ratio of 1.57 and a debt-to-equity ratio of 0.40.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The firm had revenue of $964.10 million for the quarter, compared to analyst estimates of $965.43 million. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.03 EPS for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director Bruce L. Claflin sold 200 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $540.80, for a total value of $108,160.00. Following the sale, the director now directly owns 161 shares in the company, valued at $87,068.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.11% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on IDXX. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. Morgan Stanley lowered their price objective on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a research report on Tuesday, May 14th. Barclays lowered their price objective on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research report on Thursday, May 2nd. William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a research report on Tuesday, April 9th. Finally, Stifel Nicolaus lowered their price objective on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research report on Monday, June 24th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $586.63.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.